Show simple item record

dc.contributor.authorBiswas, S
dc.contributor.authorTroy, H
dc.contributor.authorLeek, R
dc.contributor.authorChung, Y-L
dc.contributor.authorLi, Ji-Liang
dc.contributor.authorRaval, RR
dc.contributor.authorTurley, H
dc.contributor.authorGatter, K
dc.contributor.authorPezzella, F
dc.contributor.authorGriffiths, JR
dc.contributor.authorStubbs, M
dc.contributor.authorHarris, AL
dc.date.accessioned2017-11-27T16:45:22Z
dc.date.available2017-11-27T16:45:22Z
dc.date.issued2010
dc.identifier.issn1687-8450
dc.identifier.issn1687-8469
dc.identifier.urihttp://hdl.handle.net/10026.1/10311
dc.description.abstract

<jats:p>In cultured clear-cell renal carcinoma (CCRCC) 786-0 cells transfected with HIF1 (HIF-1+), HIF-2 (HIF-2+), or empty vector (EV), no significant differences were observed in the growth rates<jats:italic>in vitro</jats:italic>, but when grown<jats:italic>in vivo</jats:italic>as xenografts HIF-2 significantly increased, and HIF-1 significantly decreased growth rates, compared to EV tumors. Factors associated with proliferation were increased and factors associated with cell death were decreased in HIF-2+ tumors. Metabolite profiles showed higher glucose and lower lactate and alanine levels in the HIF-2+ tumors whilst immunostaining demonstrated higher pyruvate dehydrogenase and lower pyruvate dehydrogenase kinase 1, compared to control tumors. Taken together, these results suggest that overexpression of HIF-2 in CCRCC 786-0 tumors regulated growth both by maintaining a low level of glycolysis and by allowing more mitochondrial metabolism and tolerance to ROS induced DNA damage. The growth profiles observed may be mediated by adaptive changes to a more oxidative phenotype.</jats:p>

dc.format.extent1-14
dc.format.mediumPrint-Electronic
dc.languageen
dc.language.isoeng
dc.publisherHindawi Limited
dc.subjectRare Diseases
dc.subjectCancer
dc.subjectKidney Disease
dc.subjectBiotechnology
dc.titleEffects of HIF-1 and HIF2 on Growth and Metabolism of Clear-Cell Renal Cell Carcinoma 786-0 Xenografts
dc.typejournal-article
dc.typeJournal Article
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/20652061
plymouth.volume2010
plymouth.publication-statusPublished
plymouth.journalJournal of Oncology
dc.identifier.doi10.1155/2010/757908
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine/UoA01 Clinical Medicine
dc.publisher.placeEgypt
dcterms.dateAccepted2010-04-22
dc.identifier.eissn1687-8469
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.1155/2010/757908
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2010
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV